Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
CORe, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
J Neurol Neurosurg Psychiatry. 2023 Dec;94(12):984-991. doi: 10.1136/jnnp-2023-331748. Epub 2023 Jul 6.
Whether progression independent of relapse activity (PIRA) heralds earlier onset of secondary progressive multiple sclerosis (SPMS) and more rapid accumulation of disability during SPMS remains to be determined. We investigated the association between early PIRA, relapse-associated worsening (RAW) of disability and time to SPMS, subsequent disability progression and their response to therapy.
This observational cohort study included patients with relapsing-remitting multiple sclerosis (RRMS) from the MSBase international registry across 146 centres and 39 countries. Associations between the number of PIRA and RAW during early multiple sclerosis (MS) (the initial 5 years of MS onset) were analysed with respect to: time to SPMS using Cox proportional hazards models adjusted for disease characteristics; and disability progression during SPMS, calculated as the change of Multiple Sclerosis Severity Scores over time, using multivariable linear regression.
10 692 patients met the inclusion criteria: 3125 (29%) were men and the mean MS onset age was 32.2 years. A higher number of early PIRA (HR=1.50, 95% CI 1.28 to 1.76, p<0.001) and RAW (HR=2.53, 95% CI 2.25 to 2.85, p<0.001) signalled a higher risk of SPMS. A higher proportion of early disease-modifying therapy exposure (per 10%) reduced the effect of early RAW (HR=0.94, 95% CI 0.89 to 1.00, p=0.041) but not PIRA (HR=0.97, 95% CI 0.91 to 1.05, p=0.49) on SPMS risk. No association between early PIRA/RAW and disability progression during SPMS was found.
Early disability increase during RRMS is associated with a greater risk of SPMS but not the rate of disability progression during SPMS. The deterioration associated with early relapses represents a potentially treatable risk factor of SPMS.
Australian New Zealand Clinical Trials Registry (ACTRN12605000455662).
进展独立于复发活动(PIRA)是否预示着继发性进展型多发性硬化症(SPMS)更早发作和 SPMS 期间更快的残疾累积,仍有待确定。我们研究了早期 PIRA、残疾相关复发恶化(RAW)与 SPMS 时间、随后的残疾进展及其对治疗的反应之间的关系。
这项观察性队列研究纳入了来自 MSBase 国际注册中心的 146 个中心和 39 个国家的复发性缓解型多发性硬化症(RRMS)患者。通过 Cox 比例风险模型分析了早期多发性硬化症(MS)期间 PIRA 和 RAW 的数量与 SPMS 时间之间的关系,该模型针对疾病特征进行了调整;并通过多变量线性回归分析了 SPMS 期间残疾进展的情况,计算为随时间推移多发性硬化严重程度评分的变化。
共有 10692 名患者符合纳入标准:3125 名(29%)为男性,平均 MS 发病年龄为 32.2 岁。更多的早期 PIRA(HR=1.50,95%CI 1.28 至 1.76,p<0.001)和 RAW(HR=2.53,95%CI 2.25 至 2.85,p<0.001)预示着 SPMS 的风险更高。早期接受更多疾病修正治疗(每增加 10%)降低了早期 RAW(HR=0.94,95%CI 0.89 至 1.00,p=0.041)但不降低 PIRA(HR=0.97,95%CI 0.91 至 1.05,p=0.49)对 SPMS 风险的影响。早期 PIRA/RAW 与 SPMS 期间的残疾进展之间没有关联。
RRMS 期间的早期残疾增加与 SPMS 的风险增加相关,但与 SPMS 期间的残疾进展速度无关。早期复发相关的恶化代表了 SPMS 的一个潜在可治疗的危险因素。
澳大利亚新西兰临床试验注册(ACTRN12605000455662)。